denotes an abstract that is clinically relevant.
denotes that this is a ticketed session.
Program: Special-Interest Sessions
Hematology Disease Topics & Pathways:
clinical trials, Acute Myeloid Malignancies, Fundamental Science, AML, Clinical Practice (Health Services and Quality), Clinical Research, health outcomes research, health disparities research, Diversity, Equity, and Inclusion (DEI) , blood banking, patient-reported outcomes, Diseases, real-world evidence, Therapies, clinical procedures, Adverse Events, Myeloid Malignancies, Technology and Procedures
Hematology Disease Topics & Pathways:
clinical trials, Acute Myeloid Malignancies, Fundamental Science, AML, Clinical Practice (Health Services and Quality), Clinical Research, health outcomes research, health disparities research, Diversity, Equity, and Inclusion (DEI) , blood banking, patient-reported outcomes, Diseases, real-world evidence, Therapies, clinical procedures, Adverse Events, Myeloid Malignancies, Technology and Procedures
Monday, December 12, 2022: 4:30 PM-6:00 PM
295-296
(Ernest N. Morial Convention Center)
Chair:
Mikkael A. Sekeres, MD, University of Miami, Sylvester Comprehensive Cancer Center
Disclosures:
Sekeres: Takeda/Millenium: Membership on an entity's Board of Directors or advisory committees; Kurome: Membership on an entity's Board of Directors or advisory committees; Bristol Myers-Squibb: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees.
During this special education session, presenters will discuss the ASH guidelines on AML in Older Adults, with a focus on how emerging evidence may impact recommendations and plans for updating the guidelines as necessary.
See more of: Special-Interest Sessions